Starling Oncology (STLNW) Short-term Investments (2022 - 2024)

Starling Oncology (STLNW) has reported Short-term Investments for 3 consecutive years, with $9.9 million the latest figure, recorded in Q2 2024.

• For the quarter ending Q2 2024, Short-term Investments fell 3.42% year-over-year to $9.9 million; the trailing twelve-month figure through Jun 2024 stood at $9.9 million (down 3.42% YoY), and the FY2023 full-year result was $49.4 million, down 17.44% from the prior year.
• Short-term Investments fell to $9.9 million in Q2 2024 per STLNW's latest filing, from $29.8 million in the prior quarter.
• Across five years, Short-term Investments topped out at $59.9 million in Q3 2023 and bottomed at $9.9 million in Q2 2024.
• Historically, Short-term Investments has averaged $36.0 million across 3 years, with a median of $35.0 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Short-term Investments surged 105.38% in 2023, then fell 25.8% in 2024.
• Over 3 years, Short-term Investments stood at $59.8 million in 2022, then decreased by 17.44% to $49.4 million in 2023, then sank by 79.87% to $9.9 million in 2024.
• According to Business Quant data, Short-term Investments over the past three periods registered $9.9 million, $29.8 million, and $49.4 million for Q2 2024, Q1 2024, and Q4 2023 respectively.